William McCombe's most recent trade in Cytek BioSciences Inc was a trade of 13,051 Common Stock done . Disclosure was reported to the exchange on Nov. 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 13,051 | 84,910 | - | - | Common Stock | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 13,051 | 174,014 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 6,320 | 63,209 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 6,320 | 73,891 | - | - | Common Stock | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 4,196 | 80,714 | - | 5.5 | 23,204 | Common Stock |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 2,032 | 71,859 | - | 5.5 | 11,237 | Common Stock |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 13,051 | 187,065 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 13,051 | 72,655 | - | - | Common Stock | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 6,320 | 69,529 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 6,320 | 62,066 | - | - | Common Stock | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 5,084 | 67,571 | - | 4.1 | 20,641 | Common Stock |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 2,462 | 59,604 | - | 4.1 | 9,996 | Common Stock |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.78 per share. | 02 Jun 2025 | 35,000 | 55,746 | - | 2.8 | 97,300 | Common Stock |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 25,283 | 75,849 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 25,283 | 25,283 | - | - | Common Stock | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 9,848 | 15,435 | - | 2.7 | 26,491 | Common Stock |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 8,700 | 24,135 | - | - | Common Stock | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 8,700 | 200,116 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 3,389 | 20,746 | - | 2.7 | 9,116 | Common Stock |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 330,882 | 330,882 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 208,816 | 208,816 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 150,602 | 150,602 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | William McCombe | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 101,132 | 101,132 | - | - | Restricted Stock Units | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 20,795 | 41,588 | - | - | Restricted Stock Unit (RSU) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 20,795 | 181,199 | - | - | Common Stock | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.49 per share. | 15 Aug 2023 | 11,201 | 169,998 | - | 1.5 | 16,689 | Common Stock |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 9,935 | 160,404 | - | - | Common Stock | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 9,935 | 89,417 | - | - | Restricted Stock Unit (RSU) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 20,795 | 161,667 | - | - | Common Stock | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 20,795 | 62,383 | - | - | Restricted Stock Unit (RSU) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.86 per share. | 15 May 2023 | 11,198 | 150,469 | - | 1.9 | 20,809 | Common Stock |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 9,935 | 140,872 | - | - | Common Stock | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2023 | 9,935 | 99,352 | - | - | Restricted Stock Unit (RSU) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 9,935 | 109,287 | - | - | Restricted Stock Unit (RSU) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 9,935 | 135,205 | - | - | Common Stock | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.62 per share. | 15 Feb 2023 | 4,268 | 130,937 | - | 3.6 | 15,446 | Common Stock |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 83,178 | 83,178 | - | - | Restricted Stock Units | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2022 | 39,740 | 139,740 | - | - | Common Stock | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2022 | 39,740 | 119,222 | - | - | Restricted Stock Unit (RSU) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.61 per share. | 15 Nov 2022 | 14,470 | 125,270 | - | 2.6 | 37,835 | Common Stock |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 233,574 | 233,574 | - | - | Restricted Stock Unit (RSU) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2022 | 100,000 | 1,910,838 | - | - | Stock Option (right to buy Common Stock) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 16 May 2022 | 100,000 | 100,000 | - | 0.2 | 18,000 | Common Stock |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 158,962 | 158,962 | - | - | Restricted Stock Unit (RSU) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 2,010,838 | 2,010,838 | - | - | Stock Option (right to buy Common Stock) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 274,998 | 274,998 | - | - | Stock Option (right to buy Common Stock) | |
| Velo3D Inc Ordinary Shares | William McCombe | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2021 | 303,084 | 303,084 | - | - | Earnout Rights |